Midday trading saw Nucor shares jump over 3% after issuing strong Q2 earnings guidance of $2.55-$2.65 per share, exceeding FactSet consensus estimates of $2.36, while Steel Dynamics fell 1% after its guidance of $2.00-$2.04 per share fell short of the $2.73 analyst expectation. Affirm rose 3% following a new $3 billion loan sale facility agreement with Prudential's PGIM Fixed Income, and Bausch Health climbed 8% after nonexecutive chair John Paulson acquired 3.6 million shares, bringing his total stake to approximately 9%. Conversely, Regencell Bioscience shares dropped 26% after a significant surge earlier in the week, and Zoetis slipped 3% following a downgrade at Stifel due to anticipated revenue deceleration amid increasing competition.
Midday trading highlighted significant divergences within the steel sector: Nucor shares advanced over 3% following robust second-quarter earnings guidance of $2.55 to $2.65 per share, which surpassed the $2.36 FactSet consensus. In contrast, Steel Dynamics declined 1% as its Q2 guidance of $2.00 to $2.04 per share fell short of analyst expectations of $2.73. The biotech sector also saw notable activity; Scholar Rock Holding's shares surged nearly 15% after its experimental drug demonstrated an ability to reduce muscle loss in patients using Eli Lilly’s obesity treatment. Conversely, CERo Therapeutics Holdings experienced a sharp retraction of over 30%, likely due to profit-taking after a 188% rally the previous day driven by an FDA orphan drug designation for its acute myeloid leukemia drug. Affirm Holdings gained 3% upon announcing a new loan sale facility with Prudential's PGIM Fixed Income, allowing for the purchase of up to $500 million of Affirm's consumer loans at any one time, with a total investment of $3 billion over three years. Bausch Health shares climbed 8% after nonexecutive chair John Paulson acquired an additional 3.6 million shares, increasing his ownership to approximately 9% of the company, a significant insider buying signal. Zoetis shares slipped 3% following a downgrade to 'hold' from 'buy' by Stifel, which cited expectations of decelerating revenue growth due to increasing competition. The solar sector showed signs of a broad rebound, with Sunrun shares rising 5% despite an RBC Capital Markets downgrade, alongside gains for Enphase Energy (nearly 5%) and SolarEdge (7%). Korn Ferry's stock jumped 9% after its fourth-quarter earnings of $1.32 per share and revenue of $712 million both surpassed analyst estimates. Oracle gained over 1% after Guggenheim raised its price target, citing a potential narrative shift. Circle Internet Group, the company behind USDC, saw its stock advance almost 16% following the U.S. Senate's passage of the GENIUS bill, which establishes federal guidelines for stablecoins. Chemours shares rose 8% despite its updated Q2 adjusted EBITDA forecast of $215 million to $225 million falling below the $236 million Wall Street consensus, while Regencell Bioscience shares dropped 26% after an exceptionally sharp rally earlier in the week.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment